Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

MLA

Xianjing Chu, et al. “Correction: Co-Inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.” Molecular Cancer, vol. 22, no. 1, June 2023, pp. 1–2. EBSCOhost, https://doi.org/10.1186/s12943-023-01812-z.

APA

Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang, & Rongrong Zhou. (2023). Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials. Molecular Cancer, 22(1), 1–2. https://doi.org/10.1186/s12943-023-01812-z

Chicago

Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang, and Rongrong Zhou. 2023. “Correction: Co-Inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.” Molecular Cancer 22 (1): 1–2. doi:10.1186/s12943-023-01812-z.